Galmed Pharmaceuticals Ltd.（纳斯达克股票代码：GLMD）今日正式对外宣布，其旗下Colospan部门所研发的突破性术中组织评估技术，已在首个人体概念验证临床研究中斩获成功结果。这一里程碑式的进展，标志着该技术从理论构想迈向实际临床应用的关键一步已然落地。
在此次开创性的人体试验中，研究团队对Colospan的这项新型技术进行了严格而全面的评估。该技术旨在手术过程中为外科医生提供实时、精准的组织特性分析，从而助力更明智、更安全的手术决策。研究结果显示，该技术不仅展现了卓越的安全性能，更在有效性层面交出了令人满意的答卷，成功验证了其在临床场景中的巨大潜力。
这一成果的取得，无疑为Galmed Pharmaceuticals在精准医疗和外科手术辅助技术领域的战略布局注入了强劲动力。公司管理层对此次试验结果给予了高度评价，认为这不仅是对Colospan技术平台科学价值的有力佐证，更是为全球数百万需要接受手术治疗的患者带来了新的希望。随着概念验证阶段的圆满收官，Galmed已为进一步的临床开发和商业化路径奠定了坚实基础，未来前景令人期待。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.